entertainment -WSS

entertainment

author：entertainment 2025-09-02 22:08:58 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.

The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Susan Tousi leaves Illumina to head cancer liquid biopsy startup

WSS

AdventHealth escalates lawsuit against insurance vendor Multiplan

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Morgan Health, with ambitious aims, wants you to know it’s still here

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

explore

entertainment

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The FDA must approve intranasal treatments for anaphylaxis

Dobbs anniversary: the lost opportunity of abortion as health care

Ukraine seeks to reclaim its role as a hub for clinical trials

Guidelines to prevent youth baseball injuries need more muscle

3 trends to watch in health tech's hiring outlook for 2024

Moonlake's readout produced a cash windfall. Risks remain

The FDA must approve intranasal treatments for anaphylaxis

Drug repurposing or repositioning? The language matters

Goldman Sachs launches $650M fund for life science investments

entertainment

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

AdventHealth escalates lawsuit against insurance vendor Multiplan

3 medical device trends to watch in 2024

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

Wikipedia

Wikipedia

explore